EFB Dengue Literature Review

ZEB2

7 min read

ZEB2

Overview

ZEB2 (Zinc finger E-box-binding homeobox 2) is a transcriptional regulator induced by T-bet. In CD8⁺ T cells, ZEB2 cooperates with T-bet to programme terminal effector differentiation through repression of TCF7 (a central memory fate TF). In B cells, ZEB2 is co-expressed with T-bet in DN2 and aNAV cells, and its high expression — paired with absence of TCF7 — distinguishes the EF effector programme from the central memory-like programme of DN1/SWM cells.

Key Points from Literature

  • Highly expressed in DN2 cells: ZEB2 RNA expression is highest in DN2 cells, paralleling TBX21 (T-bet). Both are elevated above NAV, SWM, and DN1 cells (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, RNA-seq).

  • T-bet/ZEB2 cooperation model: T-bet and ZEB2 cooperate to promote effector cell differentiation through inhibition of TCF7. DN2 cells express high T-bet/ZEB2 and lack TCF7; DN1/SWM cells express TCF7 and lack T-bet/ZEB2. This dichotomy suggests DN2 and DN1 belong in distinct differentiation pathways (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, citing Dominguez et al. 2015 for T cell parallel).

  • ZEB1 distinction: ZEB1, a related zinc finger TF, is uniquely low in DN2 cells. ZEB1 binding motifs are enriched in genes with low DN2 expression (CXCR5, CD21, TRAF5), suggesting ZEB1 loss contributes to the DN2 phenotype (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • ZEB2 is the primary transcriptional driver of ABC formation: Targeted in vitro manipulation of 16 candidate TFs identified Zeb2 as the primary inducer of ABC in both mice and humans. B cell-intrinsic Zeb2 deficiency abolishes the ABC transcriptional signature (including T-bet, CD11c, Zbtb32) and the proinflammatory functions and autoimmune pathology in TLR7-driven lupus. Zeb2 haploinsufficiency in humans also reduces ABC numbers (see Sanz2025 - Human Atypical B Cells Overview, review citing Dai et al. 2024).

  • ZEB2 represses Mef2b to block GC entry: Zeb2 represses Mef2b, a TF required for GC differentiation. This provides the first direct molecular mechanism linking EF commitment to GC exclusion: high ZEB2 in aNAV/DN2 cells actively prevents GC entry. Together with the GC-independent nature of autoimmunity in TLR7 gain-of-function mice, this establishes the molecular basis for EF/GC antagonism (see Sanz2025 - Human Atypical B Cells Overview, review citing Dai et al. 2024).

  • ZEB2 can drive ABC independently of T-bet: The identification of ZEB2 as a primary driver upstream of T-bet is consistent with observations that CD11c⁺ ABC can be generated and maintained without T-bet. ZEB2 is required for T-bet expression in ABC, but may also promote ABC features through T-bet-independent mechanisms (see Sanz2025 - Human Atypical B Cells Overview).

  • ★ ZEB2 is proposed as the factor imposing a shared ABC programme across immune contexts. Independently of the Sanz2025/Dai2024 line above, a second review lineage identifies ZEB2 as “a key transcription factor involved in ABC development both in mice and humans,” explicitly linking it to the observation that ABCs from malaria, HIV, and autoimmune disease share transcriptional profiles (see Glaros2025 - Multilayered Identity of B Cell Memory, review, citing Dai 2024 Science + Gao 2024 Sci Immunol). This elevates ZEB2 from an SLE/TLR7-context driver to the leading candidate for a cross-disease ABC identity factor — and makes it the most interesting unstained TF for dengue (no dengue study has measured it; it is intranuclear, so it fits intracellular-capable panels).

  • ★ ZEB2/ABC function is dual-edged — pathogenic in autoimmunity, protective in persistent infection. B-cell-specific Zeb2 deletion improved disease outcomes in a lupus mouse model, consistent with the therapeutic framing above. But in persistent Plasmodium infection, B-cell-specific Zeb2 deletion decreased germinal-center B cell numbers, indicating that ZEB2-driven ABCs help sustain germinal centers and humoral responses in chronic infection (see Glaros2025 - Multilayered Identity of B Cell Memory, review, citing Gao 2024 Sci Immunol, mouse conditional-KO). See Contradictions below.

  • ZEB2 named as a transcriptional regulator of GC-independent responses in both mice and humans — with an explicit caveat against over-reading it. The consensus Perspective identifies ZEB2 (with T-bet) as part of a “remarkably conserved molecular and phenotypic profile” of B cells presumed to derive from GC-independent responses, alongside CD19^hi, CD20^hi, CD21^lo, CD23^lo, CXCR5^lo, FcRL5, PD-1, and CD11c. ZEB2⁺ cells appear to have undergone IFN-γ-dependent transcriptional programming, including CXCR3 induction. But the authors add: “Expression of ZEB2 and TLR7 may help define a unique B cell activation pathway, but limited data currently exist to determine whether this B cell fate and a classic EF response are always related” — i.e. ZEB2 marks a programme, and whether that programme is the extrafollicular pathway is an open question, not an established mapping (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • Song2022 reads Zeb2 as a memory-associated gene, not only as a follicular-exclusion factor. In sorted day-12 murine T-bet⁺CD11c⁺ B cells Zeb2 was highly expressed and was grouped by the authors with Mndal and Tle3 as genes associated with memory B cells (citing Bhattacharya 2007 and Laidlaw 2020), listed separately from the secretory-capability genes Prdm1, Xbp1 and Sdc1 in the same panel (see Song2022 - Tfh Outside Germinal Centers Drive T-bet CD11c B Cells, mouse, LCMV-Armstrong, sorted RNA-seq). This sits beside rather than against the CXCR5-repression reading held elsewhere on this page: the same factor is being credited with a memory-identity role in a population shown to develop without a germinal centre.

Contradictions & Debates

  • ★ ZEB2 blocks GC entry, yet ZEB2-driven ABCs sustain GCs — which is it? The wiki holds two results that pull in opposite directions:
    • GC-antagonistic: ZEB2 represses Mef2b, a TF required for GC differentiation — the molecular basis for EF/GC antagonism, with high ZEB2 in aNAV/DN2 actively preventing GC entry (see Sanz2025 - Human Atypical B Cells Overview, review citing Dai 2024).
    • GC-supporting: B-cell-specific Zeb2 deletion reduces GCBC numbers in persistent Plasmodium infection, i.e. ZEB2-dependent cells are needed to sustain the GC (see Glaros2025 - Multilayered Identity of B Cell Memory, review citing Gao 2024 — whose title states ZEB2 drives atypical B cells “to sustain germinal centers that control persistent infection”).
    • Possible reconciliation (not established): these are different levels of action. Cell-intrinsically, ZEB2 may exclude the ZEB2^hi cell itself from the GC; systemically, the ABCs it generates may support GCs of other clones — e.g. via cytokine production or antigen presentation, both documented ABC functions (see Age-Associated B Cell). The two experiments also differ in setting (TLR7-driven lupus vs persistent Plasmodium), and Glaros2025 - Multilayered Identity of B Cell Memory itself lists ABC effector route — PC differentiation vs antigen presentation to T cells vs both — as unresolved. Treat as an open contradiction, not a resolved one.
    • Therapeutic consequence: ZEB2/ABC depletion is not unidirectionally beneficial. In an infection setting it may cost humoral immunity — directly relevant if the atypical compartment is ever proposed as a dengue intervention target.

T-bet, DN2 B Cell, Activated Naive B Cell, Atypical B Cell, Age-Associated B Cell, Extrafollicular Response, Germinal Center, GC-Independent Response

Sources

Graph View

Backlinks